Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects: A Case-Control Study to Identify Potential Biomarkers of DN to Stratify Risk of Progression in T2D Patients

Carla Harkin; Diego Cobice; Simon Brockbank; Stephanie  Bolton; Frances  Johnston; Anna  Strzelecka; Joanne Watt; Mary Jo Kurth; John Lamont; Peter Fitzgerald; Tara C. B. Moore; MW Ruddock

doi:10.3389/fendo.2022.887237

Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects: A Case-Control Study to Identify Potential Biomarkers of DN to Stratify Risk of Progression in T2D Patients

Carla Harkin
, Diego Cobice
, Simon Brockbank
, Stephanie Bolton
, Frances Johnston
, Anna Strzelecka
, Joanne Watt
, Mary Jo Kurth
, John Lamont
, Peter Fitzgerald
, Tara C. B. Moore
, MW Ruddock

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

104 Downloads (Pure)

Abstract

Introduction
Currently there are no biomarkers that are predictive of when patients with type-2 diabetes (T2D) will progress to more serious kidney disease i.e. diabetic nephropathy (DN). Biomarkers that could identify patients at risk of progression would allow earlier, more aggressive treatment intervention and management, reducing patient morbidity and mortality.
Materials and methods
Study participants (N=88; control n=26; T2D n=32; DN n=30) were recruited from the renal unit at Antrim Area Hospital, Antrim, UK and Whiteabbey Hospital Diabetic Clinic, Newtownabbey, UK, between 2019 and 2020. Venous blood (30 ml) and urine (10 ml) were collected together with a detailed clinical history for each study participant.
Results
In total, 13/25 (52.0%) biomarkers measured in urine and 25/34 (73.5%) biomarkers measured in serum were identified as significantly different between control, T2D and DN participants. DN patients, were older, smoked more, had higher systolic blood pressure and higher serum creatinine levels and lower eGFR function. Serum biomarkers significantly inversely correlated with eGFR.
Conclusion
This pilot-study identified several serum biomarkers that could be used to predict progression of T2D to more serious kidney disease; namely, midkine, sTNFR1 and 2, H-FABP and Cystatin C. Our results warrant confirmation in a longitudinal study using a larger patient cohort.

Original language	English
Article number	887237
Pages (from-to)	1-11
Number of pages	11
Journal	Frontiers in Endocrinology
Volume	13
Early online date	29 Jun 2022
DOIs	https://doi.org/10.3389/fendo.2022.887237
Publication status	Published online - 29 Jun 2022

Bibliographical note

Funding Information:
This study was funded by the Randox Laboratories Ltd – Ulster University Industrial Ph.D. Academy.

Publisher Copyright:
Copyright © 2022 Harkin, Cobice, Brockbank, Bolton, Johnston, Strzelecka, Watt, Kurth, Lamont, Fitzgerald, Moore and Ruddock.

Funding

Funding Information: This study was funded by the Randox Laboratories Ltd – Ulster University Industrial Ph.D. Academy. Publisher Copyright: Copyright © 2022 Harkin, Cobice, Brockbank, Bolton, Johnston, Strzelecka, Watt, Kurth, Lamont, Fitzgerald, Moore and Ruddock.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Algorithm
diabetic nephropathy
midkine
sTNFR1
sTNFR2
L-FABP,
H-FABP
Type-2 diabetes
chronic kidney disease
kidney
L-FABP
cystatin C
type-2 diabetes

Access to Document

10.3389/fendo.2022.887237

fendo-13-887237Final published version, 2.47 MBLicence: CC BY

Fingerprint

Dive into the research topics of 'Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects: A Case-Control Study to Identify Potential Biomarkers of DN to Stratify Risk of Progression in T2D Patients'. Together they form a unique fingerprint.

Reactive aldehydes as potential biomarkers for diabetic nephropathy detection, stratification and disease progression
Harkin, C. (Author), Moore, T. (Supervisor), Cobice, D. (Supervisor) & Brockbank, S. (Supervisor), Oct 2021
Student thesis: Doctoral Thesis

File

Cite this

Harkin, C., Cobice, D., Brockbank, S., Bolton, S., Johnston, F., Strzelecka, A., Watt, J., Kurth, M. J., Lamont, J., Fitzgerald, P., Moore, T. C. B., & Ruddock, MW. (2022). Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects: A Case-Control Study to Identify Potential Biomarkers of DN to Stratify Risk of Progression in T2D Patients. Frontiers in Endocrinology, 13, 1-11. Article 887237. Advance online publication. https://doi.org/10.3389/fendo.2022.887237

@article{63b92853eea7450883cea6b5d9f1238c,

title = "Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects: A Case-Control Study to Identify Potential Biomarkers of DN to Stratify Risk of Progression in T2D Patients",

abstract = "Introduction Currently there are no biomarkers that are predictive of when patients with type-2 diabetes (T2D) will progress to more serious kidney disease i.e. diabetic nephropathy (DN). Biomarkers that could identify patients at risk of progression would allow earlier, more aggressive treatment intervention and management, reducing patient morbidity and mortality. Materials and methods Study participants (N=88; control n=26; T2D n=32; DN n=30) were recruited from the renal unit at Antrim Area Hospital, Antrim, UK and Whiteabbey Hospital Diabetic Clinic, Newtownabbey, UK, between 2019 and 2020. Venous blood (30 ml) and urine (10 ml) were collected together with a detailed clinical history for each study participant. Results In total, 13/25 (52.0\%) biomarkers measured in urine and 25/34 (73.5\%) biomarkers measured in serum were identified as significantly different between control, T2D and DN participants. DN patients, were older, smoked more, had higher systolic blood pressure and higher serum creatinine levels and lower eGFR function. Serum biomarkers significantly inversely correlated with eGFR. Conclusion This pilot-study identified several serum biomarkers that could be used to predict progression of T2D to more serious kidney disease; namely, midkine, sTNFR1 and 2, H-FABP and Cystatin C. Our results warrant confirmation in a longitudinal study using a larger patient cohort. ",

keywords = "Algorithm, diabetic nephropathy, midkine, sTNFR1, sTNFR2, L-FABP,, H-FABP, Type-2 diabetes, chronic kidney disease, kidney, L-FABP, cystatin C, type-2 diabetes",

author = "Carla Harkin and Diego Cobice and Simon Brockbank and Stephanie Bolton and Frances Johnston and Anna Strzelecka and Joanne Watt and Kurth, \{Mary Jo\} and John Lamont and Peter Fitzgerald and Moore, \{Tara C. B.\} and MW Ruddock",

note = "Funding Information: This study was funded by the Randox Laboratories Ltd – Ulster University Industrial Ph.D. Academy. Publisher Copyright: Copyright {\textcopyright} 2022 Harkin, Cobice, Brockbank, Bolton, Johnston, Strzelecka, Watt, Kurth, Lamont, Fitzgerald, Moore and Ruddock.",

year = "2022",

month = jun,

day = "29",

doi = "10.3389/fendo.2022.887237",

language = "English",

volume = "13",

pages = "1--11",

journal = "Frontiers in Endocrinology",

issn = "1664-2392",

publisher = "Frontiers",

}

Harkin, C, Cobice, D, Brockbank, S, Bolton, S, Johnston, F, Strzelecka, A, Watt, J, Kurth, MJ, Lamont, J, Fitzgerald, P, Moore, TCB & Ruddock, MW 2022, 'Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects: A Case-Control Study to Identify Potential Biomarkers of DN to Stratify Risk of Progression in T2D Patients', Frontiers in Endocrinology, vol. 13, 887237, pp. 1-11. https://doi.org/10.3389/fendo.2022.887237

Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects: A Case-Control Study to Identify Potential Biomarkers of DN to Stratify Risk of Progression in T2D Patients. / Harkin, Carla; Cobice, Diego; Brockbank, Simon et al.
In: Frontiers in Endocrinology, Vol. 13, 887237, 29.06.2022, p. 1-11.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects: A Case-Control Study to Identify Potential Biomarkers of DN to Stratify Risk of Progression in T2D Patients

AU - Harkin, Carla

AU - Cobice, Diego

AU - Brockbank, Simon

AU - Bolton, Stephanie

AU - Johnston, Frances

AU - Strzelecka, Anna

AU - Watt, Joanne

AU - Kurth, Mary Jo

AU - Lamont, John

AU - Fitzgerald, Peter

AU - Moore, Tara C. B.

AU - Ruddock, MW

N1 - Funding Information: This study was funded by the Randox Laboratories Ltd – Ulster University Industrial Ph.D. Academy. Publisher Copyright: Copyright © 2022 Harkin, Cobice, Brockbank, Bolton, Johnston, Strzelecka, Watt, Kurth, Lamont, Fitzgerald, Moore and Ruddock.

PY - 2022/6/29

Y1 - 2022/6/29

N2 - Introduction Currently there are no biomarkers that are predictive of when patients with type-2 diabetes (T2D) will progress to more serious kidney disease i.e. diabetic nephropathy (DN). Biomarkers that could identify patients at risk of progression would allow earlier, more aggressive treatment intervention and management, reducing patient morbidity and mortality. Materials and methods Study participants (N=88; control n=26; T2D n=32; DN n=30) were recruited from the renal unit at Antrim Area Hospital, Antrim, UK and Whiteabbey Hospital Diabetic Clinic, Newtownabbey, UK, between 2019 and 2020. Venous blood (30 ml) and urine (10 ml) were collected together with a detailed clinical history for each study participant. Results In total, 13/25 (52.0%) biomarkers measured in urine and 25/34 (73.5%) biomarkers measured in serum were identified as significantly different between control, T2D and DN participants. DN patients, were older, smoked more, had higher systolic blood pressure and higher serum creatinine levels and lower eGFR function. Serum biomarkers significantly inversely correlated with eGFR. Conclusion This pilot-study identified several serum biomarkers that could be used to predict progression of T2D to more serious kidney disease; namely, midkine, sTNFR1 and 2, H-FABP and Cystatin C. Our results warrant confirmation in a longitudinal study using a larger patient cohort.

AB - Introduction Currently there are no biomarkers that are predictive of when patients with type-2 diabetes (T2D) will progress to more serious kidney disease i.e. diabetic nephropathy (DN). Biomarkers that could identify patients at risk of progression would allow earlier, more aggressive treatment intervention and management, reducing patient morbidity and mortality. Materials and methods Study participants (N=88; control n=26; T2D n=32; DN n=30) were recruited from the renal unit at Antrim Area Hospital, Antrim, UK and Whiteabbey Hospital Diabetic Clinic, Newtownabbey, UK, between 2019 and 2020. Venous blood (30 ml) and urine (10 ml) were collected together with a detailed clinical history for each study participant. Results In total, 13/25 (52.0%) biomarkers measured in urine and 25/34 (73.5%) biomarkers measured in serum were identified as significantly different between control, T2D and DN participants. DN patients, were older, smoked more, had higher systolic blood pressure and higher serum creatinine levels and lower eGFR function. Serum biomarkers significantly inversely correlated with eGFR. Conclusion This pilot-study identified several serum biomarkers that could be used to predict progression of T2D to more serious kidney disease; namely, midkine, sTNFR1 and 2, H-FABP and Cystatin C. Our results warrant confirmation in a longitudinal study using a larger patient cohort.

KW - Algorithm

KW - diabetic nephropathy

KW - midkine

KW - sTNFR1

KW - sTNFR2

KW - L-FABP,

KW - H-FABP

KW - Type-2 diabetes

KW - chronic kidney disease

KW - kidney

KW - L-FABP

KW - cystatin C

KW - type-2 diabetes

UR - https://www.scopus.com/pages/publications/85134176552

U2 - 10.3389/fendo.2022.887237

DO - 10.3389/fendo.2022.887237

M3 - Article

C2 - 35846341

SN - 1664-2392

VL - 13

SP - 1

EP - 11

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

M1 - 887237

ER -

Harkin C, Cobice D, Brockbank S, Bolton S, Johnston F, Strzelecka A et al. Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects: A Case-Control Study to Identify Potential Biomarkers of DN to Stratify Risk of Progression in T2D Patients. Frontiers in Endocrinology. 2022 Jun 29;13:1-11. 887237. Epub 2022 Jun 29. doi: 10.3389/fendo.2022.887237

Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects: A Case-Control Study to Identify Potential Biomarkers of DN to Stratify Risk of Progression in T2D Patients

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Student theses

Reactive aldehydes as potential biomarkers for diabetic nephropathy detection, stratification and disease progression

Cite this